Mestag Therapeutics appoints Dr. Ton Logtenberg as a non-executive director

March 31, 2022

Cambridge, UK, March 31st, 2022 – Mestag Therapeutics (“Mestag”), a breakthrough inflammatory disease and immuno-oncology company, today announced the appointment of Dr. Ton Logtenberg as a non-executive director.

“Mestag is pioneering an extraordinary new field of biology, focused on the ability of fibroblasts to directly influence immune effector cells and mediate the immune environment,” Dr. Logtenberg commented. “I am delighted to be joining this talented and dynamic team and look forward to working with them as they build a pipeline of first-in-class therapies for cancers and inflammatory diseases.”

Ton Logtenberg is the founder and former President and CEO of Merus, a Nasdaq-listed clinical-stage biotechnology company focused on cancer. He was also the founder and CEO of U-BiSys, a Dutch biotechnology company that merged with Introgene to become Crucell, where he served as Chief Scientific Officer responsible for the discovery and development of vaccines and antibodies. Crucell was acquired by Johnson and Johnson in 2011 for $2.4 billion.

Together with Dr. Hans Clevers, Dr. Logtenberg founded the HUB foundation for organoid technology and served on the board of directors and supervisory board. He is also a Venture Partner at Forbion and Chairman of the Board of Synox Therapeutics.  Dr. Logtenberg received a PhD in immunology from Utrecht University and did his postdoctoral work at Columbia University. He was a professor of immuno-biotechnology at Utrecht University and is currently professor in Entrepreneurship in Life Sciences.

Susan Hill, PhD, Chief Executive Officer of Mestag Therapeutics, said: “As a founder of Crucell, Merus and HUB Organoids, Ton has an outstanding background both as a scientist and an entrepreneur. His experience and expertise will further strengthen our Board of Directors and provide invaluable guidance to Mestag as we continue to progress and expand our portfolio and partnerships.”

For enquiries, please contact:

Jonathan Birt

M: +44 (0)7860 361746



About Mestag Therapeutics:

Mestag’s mission is to develop impactful new medicines for patients by targeting activated fibroblast populations and their role in influencing immune effector cells in disease. Our founding investigators comprise leading experts in inflammatory disease, cancer, computational biology and fibroblast biology from the University of Oxford, Brigham & Women’s Hospital, Harvard Medical School and Cold Spring Harbor Laboratory. Mestag is progressing a pipeline of first-in-class therapeutics to interrupt fibroblast-mediated effects on immune cells in inflammatory disease and immuno-oncology.

Mestag is supported by leading global investors SV Health Investors, Johnson & Johnson Innovation – JJDC, Inc., Forbion, GV (formerly Google Ventures) and Northpond Ventures. The company is headquartered in Cambridge, UK.  In 2021, Mestag was recognised on the Fierce 15 list of  innovative biotechnology companies.

For further information please visit our website